CompoAtlas

MegaLive Hemovin Capsule

MegaLive Hemovin Capsule : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Registration number
MAL17126069TC
Type
Natural product
Published status
PRODUCT APPROVED
Licence holder
MegaLive BioSciences Sdn Bhd
Manufacturer
GN NEUTRICEUTICALS SDN. BHD.
Registration period starting
2022-12-22
Published validity end
2027-12-22

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

No point flagged by the rules applied to recognised ingredients.

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
Aesculus hippocastanumAesculus hippocastanum[150 mg,500 mg]Not identified
Ruscus aculeatusRuscus aculeatus[100 mg]Not identified
Crataegus pinnatifidaCrataegus pinnatifida[100 mg,500 mg]Not identified
Centella asiaticaCentella asiatica[50 mg,500 mg]Not identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Original register data

View published fields and their variants
Active ingredients
Aesculus hippocastanum[150 mg,500 mg],Ruscus aculeatus[100 mg],Crataegus pinnatifida[100 mg,500 mg],Centella asiatica[50 mg,500 mg]
Valid until
2027-12-22
Registration date
2022-12-22
Published description
NATURAL PRODUCT
Licence holder
MegaLive BioSciences Sdn Bhd
Producer
GN NEUTRICEUTICALS SDN. BHD.
Published name
MegaLive Hemovin Capsule
Published reference
201708290729T
Registration number
MAL17126069TC
Published status
PRODUCT APPROVED

Official source

View the official register, number MAL17126069TC

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Aesculus hippocastanum
    Read the warning, when it applies and the studies cited

    Horse Chestnut - Aesculus Hippocastanum

    Route of administration: Oral (Bradley 2006; ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    When using this product you may experience headache, dizziness, gastric irritation, or itchiness (Bradley 2006; Mills and Bone 2005; ESCOP 2003).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 February 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line